Summary

Gives the specified Executive Order the same force and effect as a law passed by Congress. That change makes the Executive Order’s regulatory-relief measures to promote domestic production of critical medicines legally binding on federal agencies, without creating new funding or other program authorizations.

Key Points

• Converts a named Executive Order on regulatory relief for domestic critical-medicine production into law.
• Makes the Executive Order’s directives legally binding on federal agencies.
• Does not provide new funding or create a new federal program.
• May speed actions to promote domestic medicine production by strengthening the Order’s legal permanence.
• Could limit future administrations’ ability to rescind the underlying Executive Order by executive action alone.
• Implementation will rely on existing agency authorities and may require follow-on rulemaking or guidance.
• Single, short provision — no additional policy details, timelines, or appropriations.
• Raises potential trade‑offs between regulatory relief and existing safety/oversight standards, depending on how agencies implement changes.